1 Pembrolizumab
was well tolerated, with 10 (17%) of 60 patients having
2 Chemotherapy
was well tolerated, with 130 (80%) of 163 patients who s
3 urrent trastuzumab and HER2/neu vaccinations
were well tolerated, with 15% of patients experiencing a
4 IL-10
was well tolerated with 22 patients completing the study
5 The regimen
was well tolerated with 26% receiving more than nine cyc
6 Vinblastine
was well tolerated with 3% of cycles associated with fev
7 Metoprolol CR/XL
was well tolerated, with 31% fewer patients withdrawn fr
8 Injections of ova-Tregs
were well tolerated, with 54 adverse events (2 related t
9 TKM-130803 infusions
were well tolerated, with 56 doses administered and only
10 The regimen
was well tolerated, with 72% of patients receiving the p
11 Treatment
was well tolerated, with 76% of patients, at 12 months,
12 Treatment
was well tolerated, with 81% of patients experiencing to
13 Rimonabant seems to
be well tolerated, with a primary side effect of mild na
14 Pertuzumab
is well tolerated with a RR of 4.3% in heavily-pretreate
15 Furthermore, exercise training
was well tolerated with a low dropout rate, and no major
16 Eluxadoline
was well tolerated with a low incidence of constipation.
17 Crizotinib
was well tolerated with a recommended phase 2 dose of 28
18 The drug
was well tolerated with a safety profile similar to that
19 Therapy
was well tolerated, with a 15% incidence of grade 3/4 he
20 Treatment
was well tolerated, with a 6-week mortality rate of 0%.
21 Sertraline treatment
was well tolerated, with a 9% discontinuation rate becau
22 Statin therapy
was well tolerated, with a low incidence of clinical adv
23 SDD
was well tolerated, with a low incidence of discontinuat
24 th ofatumumab monotherapy and this treatment
was well tolerated, with a low incidence of IgM flare.
25 th ofatumumab monotherapy and this treatment
was well tolerated, with a low incidence of IgM flare.
26 In phase 3 clinical trials, fidaxomicin
was well tolerated, with a safety profile comparable wit
27 Fluoxetine treatment for panic disorder
was well tolerated, with a safety profile consistent wit
28 Atezolizumab
was well tolerated, with a safety profile distinct from
29 Ezetimibe plus atorvastatin
was well tolerated, with a safety profile similar to ato
30 ight, with fewer hypoglycaemic episodes, and
was well tolerated, with a safety profile similar to tha
31 In all 4 trials, SC-58635
was well tolerated, with a safety profile similar to tha
32 Ceftaroline fosamil
was well tolerated, with a safety profile similar to the
33 administration of ezetimibe with simvastatin
was well tolerated, with a safety profile similar to tho
34 The drug
was well tolerated, with a slight increase in minor infe
35 Ibrutinib
was well-tolerated with a toxicity profile similar to la
36 Bet v 1 COP injections
were well tolerated, with a higher frequency of systemic
37 (90)Y hepatic treatments
are well tolerated with acceptable toxicities; tumor res
38 weekly docetaxel in conjunction with 3-D CRT
is well tolerated with acceptable toxicity.
39 The regimen
was well tolerated, with acceptable myelosuppression and
40 The Laitinen stereotactic localizer
is well tolerated with accurate reproducibility during s
41 ional HU and 5FU with IFN-alpha2a modulation
was well-tolerated with activity in gastric cancer.
42 LCZ696
was well tolerated with adverse effects similar to those
43 DAB389IL-2
is well tolerated with an MTD of 27 micrograms/kg/day.
44 Gengraf
is well tolerated, with an excellent safety profile, com
45 ion-site reactions, long-acting cabotegravir
was well tolerated with an acceptable safety profile.
46 n of cetuximab, carboplatin, and gemcitabine
was well tolerated with an acceptable toxicity profile.
47 used in stage two was 800 mg/m(2), and R-BAC
was well tolerated, with an 85% treatment completion rat
48 Ridinilazole
was well tolerated, with an adverse event profile simila
49 (131)I-MIBG plus arsenic trioxide
was well tolerated, with an adverse event profile simila
50 r HCV recurrence after liver transplantation
was well tolerated, with an overall high SVR12 rate (85%
51 CTLA4Ig
was well tolerated, with an overall safety profile simil
52 All treatment regimens
were well tolerated, with an overall incidence of grade
53 PT2385
was well tolerated, with anemia (grade 1 to 2, 35%; grad
54 The procedure
was well tolerated with anticipated cytopenias, neutrope
55 aparib is a potent, oral PARP inhibitor that
is well tolerated, with antitumor activity in BRCA1/2 mu
56 The procedure
was well tolerated with any discomfort described as mild
57 One year of 6.0 micro g/kg/wk
was well tolerated with appropriate dose modification; n
58 Both treatments
were well tolerated, with average follow-up adverse even
59 study, a single subcutaneous dose of rhIL-7
was well tolerated with biologic activity demonstrable a
60 VEGF-AS
was well tolerated, with biologic effects and preliminar
61 Brachytherapy treatment
was well tolerated, with clinically useful vision (>20/2
62 This treatment combination
was well tolerated with complete recovery of blood count
63 Each medication
was well tolerated, with completion rates and discontinu
64 Gefitinib (250 or 500 mg daily)
was well tolerated with concomitant boost RT or concurre
65 Thalidomide
was well tolerated, with constipation and sedation being
66 s completed phase-I clinical development and
was well tolerated with desirable pharmacokinetics in hu
67 Pertuzumab
was well tolerated with diarrhea in 69.1% (11.4% grade 3
68 ABT-436
was well tolerated, with diarrhea (mild-to-moderate seve
69 ZD1839
was well tolerated, with DLT observed at a dose well abo
70 Low doses of prednisone
are well tolerated, with documented side effects includi
71 combination of lenalidomide and azacitidine
is well tolerated with encouraging clinical activity.
72 AA plus prednisone
was well tolerated, with encouraging antitumor activity
73 ABR-217620
was well tolerated with evidence of immunological activi
74 Compound 1
is well tolerated, with excellent in vivo activity in HA
75 Daily doses up to 7.56 g DHA+EPA
were well tolerated with excellent compliance in this co
76 CRd
was well tolerated with exceptional response rates.
77 This pilot induction regimen
was well tolerated with expected and reversible toxiciti
78 Treatment
was well tolerated with expected hematologic toxicity an
79 VOR
was well tolerated, with exposures within expected param
80 The regimen
was well tolerated, with fatigue, mucositis, nausea/vomi
81 The new antiepileptic drugs
are well tolerated with few adverse effects, minimal dru
82 It
is well tolerated with few side effects.
83 C is highly effective at preventing haze and
is well tolerated, with few reported complications.
84 The treatment
was well tolerated with few (2.8%) grade 3 or 4 infectio
85 The procedure
was well tolerated with few adverse events.
86 The prime/boost schedule
was well tolerated with few adverse events.
87 The study drug
was well tolerated with few symptoms and related adverse
88 Lurasidone
was well tolerated, with few changes in weight or metabo
89 Sofosbuvir plus ledipasvir
was well-tolerated with few adverse events.
90 Both the treatments
were well tolerated with few reports of adverse events.
91 Both regimens
were well-tolerated with few serious side-effects.
92 Induction CIP
was well tolerated (with filgrastim support) and active
93 Treatment
was well tolerated, with five (12%) of 42 patients havin
94 Temozolomide
was well tolerated, with four (3%) patients discontinuin
95 The drug
was well tolerated, with gastrointestinal symptoms being
96 Overall, DTG
is well tolerated, with headache and insomnia being the
97 ly treated patients, full doses of cisplatin
are well tolerated with increasing doses of tirapazamine
98 Overall, rosuvastatin
was well tolerated with infrequent serious adverse cardi
99 Sertraline
was well tolerated, with insomnia the only adverse effec
100 Oral NAC
was well tolerated with limited side effects.
101 Adjuvant chemotherapy
was well tolerated, with limited toxicity.
102 sequence (46% amino acid sequence identity)
were well tolerated, with little effect on RNA synthesis
103 The 27 gauge PPV
was well tolerated with low rates of intraoperative and
104 a minimum follow-up of 1 year, 27-gauge PPV
was well tolerated with low rates of postoperative compl
105 Therapy
was well tolerated with manageable toxicities.
106 Ro 31-7453
was well tolerated, with manageable adverse effects.
107 Both agents
are well tolerated, with mild headache being the most co
108 Treatment
was well tolerated with mild to moderate hot flashes in
109 MK-0448
was well-tolerated with mild adverse experiences, most c
110 The MNs and NTX patch
were well tolerated with mild systemic and application s
111 lambda with or without daily RBV for 4 weeks
is well tolerated with minimal adverse events and hemato
112 Here, we show that JB253
is well-tolerated with minimal mutagenicity and can be u
113 Treatment
was well tolerated with minimal cardiac dysfunction.
114 Infection in normal mice
was well tolerated with minimal effects on dynamic lung
115 Treatment
was well tolerated with minimal flu-like symptoms and no
116 Therapy
was well tolerated with minimal hematologic toxicity.
117 The regimen
was well tolerated with minimal hematological toxicity.
118 Intranasal ketamine
was well tolerated with minimal psychotomimetic or disso
119 The vector
was well tolerated with minimal side effects, had a shor
120 NAC
was well tolerated, with minimal adverse events.
121 Each thermochemotherapeutic session
was well tolerated, with minimal discomfort.
122 The regimen
was well tolerated, with minimal grade 3 and 4 toxicitie
123 Locally administered sirolimus
was well-tolerated with minimal systemic exposure at all
124 Both bim/tim and dorz/brim/tim
were well tolerated with minimal ocular surface damage.
125 to sitagliptin for reduction of HbA(1c), and
was well tolerated with minimum risk of hypoglycaemia.
126 The treatment regimen in the second study
was well tolerated with minor changes in liver enzymes t
127 Both CVI 5-FU and oral eniluracil/5-FU
were well tolerated, with moderate activity in these hea
128 e-dense and metronomic temozolomide regimens
were well tolerated with modest toxicity.
129 Both treatments
were well tolerated, with more thrombocytopenia and blee
130 Once-weekly epoetin alfa
was well tolerated, with most adverse events attributed
131 Treatment
was well tolerated, with mostly grade 1 and 2 toxicities
132 CAI
was well tolerated, with mostly grade 1 to 2 toxicity.
133 Sebelipase alfa
was well tolerated, with mostly mild adverse events unre
134 Both formulations
were well tolerated with mostly mild and transient local
135 Both vaccines
were well-tolerated, with myalgia (19%), malaise (14%),
136 TPT
is well tolerated, with myelosuppression of short durati
137 The higher-dose regimen
was well tolerated, with myelosuppression being the majo
138 Treatment
was well tolerated, with nausea, vomiting, and fatigue b
139 Moreover, treatment with the alphaAnalogue
was well tolerated with neither signs of desensitization
140 Unsymmetrically substituted allenes
are well tolerated with nickel catalysis and afford Z al
141 Both
are well tolerated, with no significant adverse effects
142 s in studies of up to 12 weeks, ETC-1002 has
been well tolerated with no serious adverse effects.
143 ing prolonged exposure, 40 mg of pravastatin
is well tolerated, with no excess of noncardiovascular s
144 ementation as long-term MitoQ administration
is well-tolerated with no reported side effects in mice
145 studies, [(18) F]Nifene (185 MBq; <0.10 mug)
was well tolerated with no adverse effects.
146 RCE
was well tolerated with no adverse events.Twice daily RC
147 py as well as treatment with dendrimer alone
was well tolerated with no apparent signs of toxicity in
148 fficacy studies for periods of up to 65 days
was well tolerated with no apparent toxicity or signific
149 Treatment
was well tolerated with no DLTs observed.
150 T-DM1
was well tolerated with no dose-limiting cardiotoxicity.
151 The treatment
was well tolerated with no dose-related toxicity other t
152 AVI-4658
was well tolerated with no drug-related serious adverse
153 stemic arterial pressure (-11%; P<0.001) but
was well tolerated with no episodes of symptomatic hypot
154 Therapy
was well tolerated with no increase in serious adverse e
155 Therapy
was well tolerated with no infectious pulmonary complica
156 Importantly, the transplant
was well tolerated with no negative clinical side effect
157 therapeutic NSAA at both 48 and 72 hours and
was well tolerated with no reports of hemorrhage, thromb
158 The treatment
was well tolerated with no safety concerns identified.
159 PEP
was well tolerated with no serious adverse effects.
160 SMC
was well tolerated with no serious adverse reactions att
161 Xenodiagnosis
was well tolerated with no severe adverse events.
162 The addition of GO
was well tolerated with no significant increase in toxic
163 Overall, pimavanserin
was well tolerated with no significant safety concerns o
164 Treatment
was well tolerated with no study agent-related serious a
165 -induced anticoagulation in healthy men, and
was well tolerated with no unexpected or clinically rele
166 rFIX
was well tolerated, with no associated thrombotic events
167 The combination of pidilizumab and rituximab
was well tolerated, with no autoimmune or treatment-rela
168 AKB-9778
was well tolerated, with no clear by-treatment differenc
169 n this critically ill population, dilmapimod
was well tolerated, with no clinically relevant safety f
170 The vaccine
was well tolerated, with no difference in adverse event
171 Zidovudine in either dose
was well tolerated, with no difference in efficacy or to
172 The intervention
was well tolerated, with no differences between active a
173 Simvastatin
was well tolerated, with no differences between the plac
174 ChimeriVax-JE
was well tolerated, with no differences in adverse event
175 Etanercept
was well tolerated, with no dose-limiting toxic effects.
176 Intracavitary administration
was well tolerated, with no dose-limiting toxicities obs
177 MABp1
was well tolerated, with no dose-limiting toxicities or
178 Epratuzumab
was well tolerated, with no dose-limiting toxicity.
179 at loss of RBPj in mature excitatory neurons
was well tolerated, with no evidence for neurodegenerati
180 FR104
was well tolerated, with no evidence of cytokine-release
181 r than mild, transient sedation, risperidone
was well tolerated, with no evidence of extrapyramidal e
182 Fluvastatin
was well tolerated, with no evidence of myopathy, rhabdo
183 Cell infusion
was well tolerated, with no evidence of short-term hemod
184 9%), compared with inhaled oxygen (64%), and
was well tolerated, with no evidence of systemic effects
185 Therapy
was well tolerated, with no grade 3 or 4 adverse events
186 Cooling
was well tolerated, with no hemodynamic instability or i
187 DBMC infusion
was well tolerated, with no increase in infectious episo
188 The administration of (18)F-FPPRGD2
was well tolerated, with no marked effects on vital sign
189 l stability and disease progression criteria
was well tolerated, with no new safety concerns identifi
190 At 144 weeks of treatment, ivacaftor
was well tolerated, with no new safety concerns.
191 of the WT C. elegans NIPA1 homolog (CeNIPA)
was well tolerated, with no obvious impact on neuronal m
192 Overall, the vaccine
was well tolerated, with no serious adverse events.
193 Treatment
was well tolerated, with no serious adverse events.
194 Ezetimibe
was well tolerated, with no serious treatment-related ad
195 rtraline, at a mean endpoint dose of 137 mg,
was well tolerated, with no sertraline-related adverse e
196 Treatment
was well tolerated, with no significant acute side effec
197 Risedronate
was well tolerated, with no significant differences in a
198 Etanercept
was well tolerated, with no significant differences in r
199 Vaccination
was well tolerated, with no significant local or systemi
200 Treatment
was well tolerated, with no treatment-related mortalitie
201 Rituximab
was well tolerated, with no treatment-related severe or
202 Overall, the treatment
was well-tolerated with no evidence of significant pulmo
203 HZ/su
was well-tolerated, with no safety concerns raised withi
204 Citalopram
was well-tolerated, with no significant negative adverse
205 Interventions
were well tolerated with no abnormalities in safety meas
206 All treatments
were well tolerated with no difference in the frequency
207 HER2-CAR T-cell infusions
were well tolerated with no dose-limiting toxicity.
208 Both drugs
were well tolerated with no safety concerns.
209 Treatments
were well tolerated with no safety concerns.
210 or co-administered with the adjuvant GM-CSF,
were well tolerated with no serious adverse events.
211 Study drugs
were well tolerated with no serious adverse events.
212 Maintenance gemcitabine and erlotinib
were well tolerated with no unexpected adverse events.
213 Overall, treatments
were well tolerated with no unexpected adverse events.
214 Infusions
were well tolerated, with no dose-limiting toxic effects
215 All doses of eltoprazine
were well tolerated, with no major adverse effects.
216 Both products
were well tolerated, with no serious adverse events rela
217 All injections
were well tolerated, with no serious adverse events repo
218 The vaccines
were well tolerated, with no serious adverse events; 80%
219 Both treatments
were well tolerated, with no significant differences in
220 Study injections
were well tolerated, with no significant differences in
221 Anti-D immunoglobulin
is well tolerated, with occasional adverse reactions sim
222 The approach
was well tolerated with only low-grade fever, myalgias,
223 The study drug
was well tolerated with only one patient developing acut
224 Early vasopressin use
was well tolerated with only one serious adverse event p
225 Treatment with rituximab
was well tolerated, with only 1 patient experiencing gra
226 Vector administration
was well tolerated, with only mild local reactions and 1
227 Otherwise, the drug
was well tolerated, with only modest elevations of liver
228 Treatment
was well tolerated, with only one death on each arm attr
229 Overall, the drug
was well tolerated, with only one grade 4 toxicity (hypo
230 The regimen
was well tolerated, with only seven hospitalizations for
231 GLP-1
was well tolerated, with only transient gastrointestinal
232 Antibody-based conditioning
was well tolerated, with only two cases of grade 3 and n
233 Treatment
was well tolerated, with only two episodes of grade 3 to
234 This in situ vaccination maneuver
was well-tolerated with only grade 1 to 2 local or syste
235 Treatments
were well tolerated with only mild discomfort.
236 The vaccine
was well tolerated, with pain at the injection site bein
237 stration of Id-pulsed DC and Id/KLH vaccines
were well tolerated with patients experiencing only mino
238 In this first-in-man study, AEG35156
was well tolerated, with predictable toxicities, pharmac
239 inutuzumab induction and maintenance therapy
was well tolerated with promising efficacy in this heter
240 Alectinib
was well tolerated, with promising antitumour activity i
241 As monotherapy, MK-8776
was well tolerated, with QTc prolongation (19%), nausea
242 Crizotinib
is well tolerated with rapid, durable responses in patie
243 RISCT
was well tolerated with rapid engraftment, short inpatie
244 Co-trimoxazole
was well tolerated with rare (<2% per person-year) adver
245 L-Methylfolate
was well tolerated, with rates of adverse events no diff
246 Evolocumab
was well tolerated, with rates of adverse events similar
247 Treatment
was well tolerated with reactogenicity rates similar to
248 eveloped countries have demonstrated that it
is well tolerated with regard to intussusception and oth
249 It
was well tolerated with repeated oral administration at
250 CRd at the MPD
was well tolerated with robust, rapid, and durable respo
251 All doses of Hematide
were well tolerated, with safety profiles similar to tho
252 BIIB074
was well tolerated, with similar adverse events in the d
253 Treatment
was well tolerated, with similar safety profiles in the
254 Both treatment regimens
were well tolerated, with similar patterns of adverse re
255 Both regimens
were well-tolerated with similar adverse events.
256 Ibrutinib, a novel BTK-targeting inhibitor,
is well tolerated, with substantial activity across B-ce
257 Substitutions to the carboline cap group
were well-tolerated with substitution at the 2-position
258 AZD6244
was well tolerated with target inhibition demonstrated a
259 Early MMR vaccination
is well tolerated, with the lowest AE frequencies found
260 The dual treatment regimen
was well tolerated, with the expected safety profile for
261 Preladenant
was well tolerated, with the most common adverse event t
262 Alectinib
was well tolerated, with the most common adverse events
263 Etirinotecan pegol
was well tolerated, with the most common grade 3 to 4 AE
264 Adjuvant imatinib
was well tolerated, with the most common serious events
265 ARQ 197
was well tolerated, with the most common toxicities bein
266 Treatment
was well tolerated, with the principal toxicity being he
267 Lenalidomide
was well tolerated; with the exception of neutropenia, g
268 Treatment
was well tolerated, with toxicities principally infusion
269 Chemotherapy
was well tolerated, with transfusion, neutropenic fever,
270 Sirolimus
was well tolerated with very few side effects.